$NVCR

NovoCure (NVCR) received approval in Japan for its Optune Pax device for pancreatic cancer treatment. The stock has declined recently, trading at $14.97, which is 69% below the $48.93 fair value estimate by analysts. The company's unique position in non-invasive cancer therapy and potential for long-term growth are highlighted, but execution risks remain.

Novocure received approval from Japan's MHLW for Optune Pax to treat unresectable locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel. The approval follows Phase 3 PANOVA-3 trial results showing improved median overall survival and delayed pain progression. The safety profile included expected skin events. According to the company, no new systemic safety signals were observed.

NovoCure Ltd (NVCR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer Baar, Switzerland – October 1, 2026 – Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Op

NovoCure Limited (NVCR) shares rose 28% after reporting Q2 2026 results with record revenues of $183.6M, up 16% YoY, and a narrowed net loss of $15.7M. The company raised its full-year revenue forecast to $710–$725M. CEO Frank Leonard highlighted strong performance and growth prospects, including upcoming FDA decisions and European launches. NVCR stock is up 55% YTD.

NovoCure Ltd (NVCR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) Timothy Scannell, a current director of NovoCure Limited (the “Company”), has retired from the Board and his seat was f

Novocure (NVCR) reported a cybersecurity incident in mid-August 2026, exposing patient data and employee information. The company stated that medical devices were not accessed and operations remained unaffected. NVCR shares have risen 3.2% since the announcement and 38.8% year-to-date. The company does not expect a material financial impact. The incident is part of a broader trend in the healthcare and medtech industry.

U.S. stock futures mostly rose late Wednesday as traders reacted to a strong January jobs report and a House vote to rescind Trump's Canadian tariffs. VKTX shares jumped 9% after announcing late-stage obesity drug trials. CRM hit a 52-week low amid AI concerns. NVCR surged 30% after FDA approval for a pancreatic cancer treatment. QS rose 10% despite reporting a quarterly loss. Retail investors increased purchases of software stocks, with IGV seeing record activity. The 10-year Treasury yield ros

Novocure, an oncology company, reported a cyberattack in mid-August that exposed records of over 1,400 U.S. patients. The breach included patient ID numbers, contact info, and some additional identifying data for fewer than 50 patients. The company stated that medical devices were unaffected and financial impact is not expected. Novocure has activated its cybersecurity response plan and initiated an investigation.

NovoCure Ltd (NVCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. In mid-August 2026, NovoCure Limited (the "Company," "we," or "us") through a subsidiary, became aware of unauthorized access to some of its information systems. Upon detecting the unauthorized access, the Company activated its cybersecurity response plan,

NovoCure (NVCR) reported Q2 net revenue of $183.58M and a net loss of $15.66M, and raised its 2026 net revenue outlook to $710M–$725M. The company said it received a CE Mark for Optune Pax in locally advanced pancreatic cancer and expects FDA premarket approval for TTFields in brain metastases from NSCLC.